The Food and Drug Administration (FDA) has approved ArmonAir® Digihaler (fluticasone propionate; Teva) for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
The ArmonAir Digihaler contains fluticasone, a corticosteroid, as an inhalation powder for oral inhalation. The product has a built-in electronic module which detects, records, and stores data on inhaler events, including peak inspiratory flow rate, for transmission to a companion mobile application (using Bluetooth® wireless technology) where inhaler events are categorized.
Using the app, patients can then review and share data with their healthcare providers as well as schedule dosing reminders; use of the app is not required for administration. “Enabling patients to track their inhaler use data, including frequency and inspiratory flow rates, each time they use their inhaler, can play a significant role in helping me have open, informed conversations with them about how best to manage their condition,” said Dr Nabeel Farooqui, MD, FAAAAI, FACAAI, Assistant Professor, Department of Medicine, Indiana University School of Medicine.
ArmonAir Digihaler is expected to be available later this year in 55mcg, 113mcg, and 232mcg strengths. Teva’s Digital Inhaler portfolio also contains ProAir® Digihaler (albuterol sulfate) and AirDuo® Digihaler (fluticasone propionate and salmeterol).
For more information visit tevapharm.com.
This article originally appeared on MPR